Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

AB Science SA (Euronext - FR0010557264 - AB) today reports its revenues for the year 2024 and provides an update on its activities. CLINICAL DEVELOPMENT KEY EVENTS DURING THE YEAR 2024 AND SINCE ...

Coherus BioSciences, Inc.’s CHRS share price has surged by 6.33%, which has investors questioning if this is right time to sell.

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.84%, which has investors questioning if this is right time to buy.

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...

0% RR in pts who did not receive sargramostim as adjuvant Cohort II: 12 pts had decrease in PSA (median decline, 32%); 1 pt had >99 ... macrophage colony-stimulating factor; BCG = bacillus ...

The Cleveland Cavaliers got their usual contributions from All-Stars Donovan Mitchell and Darius Garland. The difference, however, was the play of Ty Jerome. He finished with 28 points, five ...

The Toronto Maple Leafs clinched their first-ever Atlantic Division title by shutting out the Buffalo Sabres 4-0 at KeyBank Center on Tuesday night. It officially confirmed the much-anticipated ...

platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, and c-KIT inhibitor. The company is currently conducting a Phase 3 clinical trial called the PROSERA Study ...